MonTa Biosciences adds $3.4M in strategic investment from Consolidated Biosciences.
MonTa Biosciences, a Copenhagen, Denmark-based biotech company, announced closing in a DKK 22.5M ($3.4M) capital investment round.
The money was provided by Ib Kunøe, through his company Consolidated Biosciences, part of the Consolidated Holdings A/S. Funding will be used to advance the company's pre-clinical trials made on mice, part of the efforts of the development of cancer immunotherapy solutions.
MonTa Biosciences, founded in 2014 by by CEO Simon Skjøde Jensen, is a spin-out from a joint collaboration between DTU Nanotech and Bioneer A/S Jensen. The company develops products within cancer immunotherapy.
MonTa has received pre-seed grants from Novo Seeds and Copenhagen Spin outs. In 2016, MonTa Biosciences and DTU, Rigshospitalet and two other companies received the Innovation Foundation's Grand Solutions grant. In January 2017, MonTa Biosciences closed a $290k investment from Pre-Seed Ventures with the help of Accelerace and NOME.